Target intelligence / Profile preview

Picornaviral capsid protein VP1 (VP1)

Target
VP1
Molecular classification
Viral structural protein, Capsid protein
01

Overview

The Picornaviral capsid protein VP1 is a primary structural protein that forms the icosahedral shell of viruses within the Picornaviridae family, such as Rhinovirus, Enterovirus, and Poliovirus (UniProt: P03303). It is essential for viral pathogenesis, as it mediates host cell receptor recognition and the subsequent entry of the virus into the cell (PubMed: 2643595). VP1 contains a conserved hydrophobic pocket that naturally accommodates "pocket factors" (typically fatty acids), which regulate the stability of the viral particle (PubMed: 11742400). This pocket is a well-validated therapeutic target for small-molecule antivirals called capsid binders, such as pleconaril and pocapavir, which displace the natural pocket factor to over-stabilize the capsid or block receptor binding (PubMed: 15105405). By preventing the conformational changes necessary for viral uncoating, these drugs effectively halt the release of the viral genome into the host cytoplasm (PubMed: 17110217). However, the clinical utility of targeting VP1 is often challenged by the rapid emergence of resistance mutations within the binding pocket and the high degree of sequence diversity among different picornavirus serotypes.

Other names
Viral protein 1VP1 structural proteinPicornavirus VP1Capsid protein VP1
02

Mechanism of action

Capsid stabilization and inhibition of viral uncoating through binding to a hydrophobic pocket within the VP1 protein.

03

Biological functions

Viral attachmentReceptor bindingViral uncoatingHost cell entryGenome delivery
04

Disease associations

InfectionCommon coldPoliomyelitisHand-foot-and-mouth diseaseMeningitisMyocarditis
05

Safety considerations

Rapid emergence of drug resistanceLimited serotype coverageDrug-drug interactions (e.g., CYP3A4 induction by pleconaril)
06

Interacting drugs

Pleconaril

4 more in the full profile.

07

Biomarkers

Viral RNA loadVP1 sequence mutationsNeutralizing antibody titers

Beyond the preview

Go deeper on Picornaviral capsid protein VP1 (VP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Picornaviral capsid protein VP1 (VP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call